Drug Information
General Information | ||||||
---|---|---|---|---|---|---|
Drug ID |
DR00102
|
|||||
Drug Name |
Dinoprostone
|
|||||
Synonyms |
(15S)-Prostaglandin E2; (5Z,11-alpha,13E,15S)-11,15-Dihydroxy-9-oxoprosta-5,13-dien-1-oic acid; (5Z,11.alpha.,13E,15S)-11,15-Dihydroxy-9-oxoprosta-5,13-dien-1-oic acid; (5Z,11alpha,13E,15S)-11,15-Dihydroxy-9-oxoprosta-5,13-dien-1-oic; (5Z,11alpha,13E,15S)-11,15-Dihydroxy-9-oxoprosta-5,13-dienoic acid; (5Z,11alpha,13E,15S)-11,15-dihydroxy-9-oxoprosta-5,13-dien-1-oic acid; (5Z,13E)-(15S)-11alpha,15-Dihydroxy-9-oxoprost-13-enoate; (5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprosta-5,13-dienoate; (5Z,13E,15S)-11alpha,15-dihydroxy-9-oxoprosta-5,13-dien-1-oic acid; (E,Z)-(1R,2R,3R)-7-(3-Hydroxy-2-((3S)-(3-hydroxy-1-octenyl))-5-oxocyclopentyl)-5-heptenoic acid; (Z)-7-[(1R,2R,3R)-3-Hydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]-5-oxocyclopentyl]hept-5-enoic acid; 5-Heptenoic acid, 7-(3-hydroxy-2-(3-hydroxy-1-octenyl)-5-oxocyclopentyl)-(8CI); 7-(3-Hydroxy-2-(3-hydroxy-1-octenyl)-5-oxocyclopentyl)-5-heptenoic acid; Alpha, PGE2; Alpha, Prostaglandin E2; BML1-F07; BMS-279654 & PGE2; Cervidil; Cervidil (TN); Dinoproston; Dinoprostona; Dinoprostona [INN-Spanish]; Dinoprostone (JAN/USP/INN); Dinoprostone Prostaglandin E2; Dinoprostone [USAN:INN:BAN:JAN]; Dinoprostone beta-Cyclodextrin Clathrate; Dinoprostonum; Dinoprostonum [INN-Latin]; E2 alpha, Prostaglandin; E2, Prostaglandin; E2alpha, Prostaglandin; Gel, Prepidil; L-7-(3-Hydroxy-2-(3-hydroxy-1-octenyl)-5-oxocyclopentyl)-5-heptenoic acid; L-PGE2; L-Prostaglandin E2; Minprositin E2; Minprostin E2; PGE2; PGE2 alpha; PGE2alpha; Prepidil; Prepidil (TN); Prepidil Gel; Propess; Propess (TN); Prostaglandin E2; Prostaglandin E2 alpha; Prostaglandin E2alpha; Prostarmon E2; Prostarmon E;Prostin E; Prostenon; Prostin; Prostin E2; Prostin E2 (TN); U 12062; U-12062; [3H]PGE2
|
|||||
Drug Type |
Small molecular drug
|
|||||
Indication | Medical abortion [ICD11: JA00.1] | Approved | [1] | |||
Therapeutic Class |
Prostaglandins
|
|||||
Structure |
|
|||||
3D MOL | 2D MOL | |||||
Formula |
C20H32O5
|
|||||
Canonical SMILES |
CCCCCC(C=CC1C(CC(=O)C1CC=CCCCC(=O)O)O)O
|
|||||
InChI |
InChI=1S/C20H32O5/c1-2-3-6-9-15(21)12-13-17-16(18(22)14-19(17)23)10-7-4-5-8-11-20(24)25/h4,7,12-13,15-17,19,21,23H,2-3,5-6,8-11,14H2,1H3,(H,24,25)/b7-4-,13-12+/t15-,16+,17+,19+/m0/s1
|
|||||
InChIKey |
XEYBRNLFEZDVAW-ARSRFYASSA-N
|
|||||
CAS Number |
CAS 363-24-6
|
|||||
Pharmaceutical Properties | Molecular Weight | 352.5 | Topological Polar Surface Area | 94.8 | ||
Heavy Atom Count | 25 | Rotatable Bond Count | 12 | |||
Hydrogen Bond Donor Count | 3 | Hydrogen Bond Acceptor Count | 5 | |||
XLogP |
2.8
|
|||||
PubChem CID | ||||||
PubChem SID |
103176817
, 10321741
, 104017641
, 104046436
, 14778621
, 14900948
, 24898100
, 24898683
, 24898775
, 26753268
, 26753269
, 26753270
, 26759401
, 3139923
, 3727087
, 3863
, 39289526
, 4265954
, 439749
, 450259
, 46505549
, 47662021
, 47810515
, 47885164
, 48415907
, 50026789
, 50087222
, 50105678
, 50105679
, 53789659
, 56313306
, 56314112
, 56459056
, 57357707
, 599053
, 75054349
, 7847147
, 7979101
, 803734
, 8143217
, 85789494
, 85856640
, 8616235
, 92298396
, 92308753
, 92309906
, 92722489
, 99300820
, 99302338
, 99431525
|
|||||
ChEBI ID |
ChEBI:15551
|
|||||
TTD Drug ID | ||||||
DT(s) Transporting This Drug | MRP2 | Transporter Info | Multidrug resistance-associated protein 2 | Substrate | [2] | |
MRP4 | Transporter Info | Multidrug resistance-associated protein 4 | Substrate | [3] | ||
OAT1 | Transporter Info | Organic anion transporter 1 | Substrate | [4] | ||
OAT2 | Transporter Info | Organic anion transporter 2 | Substrate | [4] | ||
OAT3 | Transporter Info | Organic anion transporter 3 | Substrate | [4] | ||
OAT4 | Transporter Info | Organic anion transporter 4 | Substrate | [4] | ||
OATP1A2 | Transporter Info | Organic anion transporting polypeptide 1A2 | Substrate | [5] | ||
OATP1B1 | Transporter Info | Organic anion transporting polypeptide 1B1 | Substrate | [6] | ||
OATP1C1 | Transporter Info | Organic anion transporting polypeptide 1C1 | Substrate | [7] | ||
OATP2A1 | Transporter Info | Organic anion transporting polypeptide 2A1 | Substrate | [8] | ||
OATP2B1 | Transporter Info | Organic anion transporting polypeptide 2B1 | Substrate | [8] | ||
OATP3A1 | Transporter Info | Organic anion transporting polypeptide 3A1 | Substrate | [9] | ||
OATP4A1 | Transporter Info | Organic anion transporting polypeptide 4A1 | Substrate | [8] | ||
OATP5A1 | Transporter Info | Organic anion transporting polypeptide 5A1 | Substrate | [10] | ||
OCT-1 | Transporter Info | Organic cation transporter 1 | Substrate | [11] | ||
OCT-2 | Transporter Info | Organic cation transporter 2 | Substrate | [11] | ||
OSTalpha | Transporter Info | Organic solute transporter subunit alpha | Substrate | [12] | ||
OSTalpha | Transporter Info | Organic solute transporter subunit alpha | Substrate | [12] | ||
OSTbeta | Transporter Info | Organic solute transporter subunit beta | Substrate | [12] | ||
OSTbeta | Transporter Info | Organic solute transporter subunit beta | Substrate | [12] | ||
Drug-Transporter Activity Data | ||||||
Drug-Transporter Activity Data | MRP4 | Transporter Info | Km = 3.4 microM | Spodoptera frugiperda (Sf9) cells-MRP4 | [3] | |
OAT1 | Transporter Info | Km = 0.97 microM | Proximal tubule (S2) cells-OAT1 | [4] | ||
OAT2 | Transporter Info | Km = 0.713 microM | Proximal tubule (S2) cells-OAT2 | [4] | ||
OAT3 | Transporter Info | Km = 0.345 microM | Proximal tubule (S2) cells-OAT3 | [4] | ||
OAT4 | Transporter Info | Km = 0.154 microM | Proximal tubule (S2) cells-OAT4 | [4] | ||
OCT-1 | Transporter Info | Km = 0.657 microM | Proximal tubule (S2) cells-OCT1 | [4] | ||
OCT-2 | Transporter Info | Km = 0.0289 microM | Proximal tubule (S2) cells-OCT2 | [4] | ||
References | ||||||
1 | Dinoprostone was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
2 | Multidrug resistance associated protein 2 mediates transport of prostaglandin E2. Liver Int. 2006 Apr;26(3):362-8. | |||||
3 | The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs. Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9244-9. | |||||
4 | Human organic anion transporters and human organic cation transporters mediate renal transport of prostaglandins. J Pharmacol Exp Ther. 2002 Apr;301(1):293-8. | |||||
5 | Localization of organic anion transporting polypeptide 4 (Oatp4) in rat liver and comparison of its substrate specificity with Oatp1, Oatp2 and Oatp3. Pflugers Arch. 2001 Nov;443(2):188-95. | |||||
6 | Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011 Mar;63(1):157-81. | |||||
7 | Identification of a novel human organic anion transporting polypeptide as a high affinity thyroxine transporter. Mol Endocrinol. 2002 Oct;16(10):2283-96. | |||||
8 | Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. Biochem Biophys Res Commun. 2000 Jun 24;273(1):251-60. | |||||
9 | Molecular characterization of human and rat organic anion transporter OATP-D. Am J Physiol Renal Physiol. 2003 Dec;285(6):F1188-97. | |||||
10 | Expression and regulation of prostaglandin transporters, ATP-binding cassette, subfamily C, member 1 and 9, and solute carrier organic anion transporter family, member 2A1 and 5A1 in the uterine endometrium during the estrous cycle and pregnancy in pigs. Asian-Australas J Anim Sci. 2017 May;30(5):643-652. | |||||
11 | Are organic cation transporters capable of transporting prostaglandins? Naunyn Schmiedebergs Arch Pharmacol. 2005 Aug;372(2):125-30. | |||||
12 | Functional complementation between a novel mammalian polygenic transport complex and an evolutionarily ancient organic solute transporter, OSTalpha-OSTbeta. J Biol Chem. 2003 Jul 25;278(30):27473-82. |
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.